Perindopril

Subscribe to Selected New Research on Perindopril

757 relevant articles (166 outcomes, 304 trials/studies) found for this Drug

Description: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.

Also Known As:

Perindopril Erbumine; Perstarium; Pirindopril; S 9490-3; S-9490; Erbumine, Perindopril; S 9490; S 9490 3; S 94903; S9490; 1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25

2-Ring Heterocyclic Compounds

Experts

1.	Ferrari, Roberto: 8 articles (11/2007 - 01/2005)
2.	Remme, Willem J: 6 articles (11/2007 - 05/2002)
3.	Chalmers, John: 6 articles (10/2007 - 05/2003)
4.	Simoons, Maarten L: 5 articles (11/2007 - 04/2006)
5.	Deckers, Jaap W: 4 articles (11/2007 - 04/2006)
6.	Bertrand, Michel: 4 articles (11/2007 - 04/2006)
7.	Neal, Bruce: 4 articles (10/2007 - 05/2003)
8.	MacMahon, Stephen: 4 articles (10/2005 - 05/2003)
9.	Woodward, Mark: 4 articles (10/2005 - 05/2003)
10.	Yoshiji, Hitoshi: 4 articles (02/2005 - 03/2002)

Related Diseases

1.	Stroke (Strokes) 07/01/1997 - "The PROGRESS ("Perindopril Protection Against Recurrent Stroke Study") study has been designed and is under way to collect information on this important issue of the antihypertensive treatment, its purpose being to evaluate the blood pressure lowering effects with an ACE-inhibitor on recurrent stroke in an overall population of 6000 patients with a positive history of previous cerebral ischemic attacks or stroke." 06/01/2006 - "METHODS: The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, placebo-controlled trial that established the beneficial effects of BP lowering in 6105 patients with cerebrovascular disease. " 10/01/2005 - "METHODS: This study was a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS)--a randomized, placebo-controlled trial that established the beneficial effects of blood pressure--lowering in a heterogeneous group of patients with cerebrovascular disease. " 01/01/2001 - "Perindopril 4 to 8 mg once daily significantly decreased carotid-femoral aortic pulse wave velocity (PWV), improved arterial compliance, reduced left ventricular mass index and, in patients with recent cerebral ischaemia and/or stroke, preserved cerebral blood flow despite significantly reducing SBP and DBP. " 12/01/1996 - "CONCLUSION: Chronic treatment with perindopril is beneficial for the prevention of stroke in SPSHR, through the preservation of the myogenic response properties of the cerebral arteries, and the attenuation of tissue damage in the brain and kidneys." Order ALL the reference details at left...
2.	Hypertension (High Blood Pressure) 08/01/1996 - "Perindopril fully prevented the development of hypertension in LH rats, suppressed their preglomerular vasoconstriction, and markedly improved their pressure-natriuresis. " 01/01/2001 - "Results from ongoing studies will help confirm the place of perindopril in the treatment of hypertension; currently, it is an effective and well tolerated treatment for patients with mild to moderate essential hypertension." 08/01/1994 - "CONCLUSION: This trial shows that ACE-inhibition with perindopril represents a simple, safe, and effective short-term therapeutic option for the large proportion of patients with mild essential hypertension and concomitant diseases and therapies." 01/01/2001 - "Perindopril monotherapy was also effective in the elderly and in patients with hypertension and concomitant disease. " 04/01/1995 - "CONCLUSION: A 12-week treatment of adult SHR with perindopril was effective in causing a permanent prevention of hypertension, amelioration of some of the tissue damage associated with hypertension and an increase in the lifespan of these rats." Order ALL the reference details at left...
3.	Heart Failure 10/01/2006 - "However, improved symptoms and exercise capacity and fewer hospitalizations for heart failure in the first year were observed on perindopril, during which most patients were on assigned therapy, suggesting that it may be of benefit in this patient population." 01/01/2002 - "In randomised, double-blind, placebo-controlled clinical trials conducted over 3 months and a large noncomparative study (up to 30 months), perindopril 4mg once daily significantly increased exercise tolerance and reduced symptoms of heart failure in patients with mild to moderate CHF. " 01/01/2002 - "Perindopril 4mg significantly improved a range of haemodynamic parameters in single-dose and long-term (8 weeks and 3 months) studies involving patients with congestive heart failure (CHF), with little or no effect on blood pressure or heart rate. " 11/01/2005 - "Although mortality and hospitalization for congestive heart failure were not affected significantly by 1-year 8 mg/day of perindopril treatment, a significant beneficial treatment-related effect was observed on left ventricular remodeling. " 01/01/2003 - "CONCLUSIONS: An efficient dose for heart failure is simply and safely obtained with perindopril, with a significant improvement in the NYHA functional class and in the radiological cardio-thoracic index." Order ALL the reference details at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 09/06/2003 - "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)." 04/01/2007 - "Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease." 04/01/2009 - "METHODS: The PERindopril GENEtic association study (PERGENE) is a substudy of the EUROPA trial, a randomized double-blind placebo-controlled multicentre clinical trial which demonstrated a beneficial effect of the ACE-inhibitor perindopril in reducing cardiovascular morbidity and mortality in 12.218 patients with stable coronary artery disease (mean follow-up 4.2 years). " 02/01/2009 - "BACKGROUND: The European trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease (EUROPA) demonstrated the benefits of perindopril with respect to secondary prevention of cardiovascular risk in patients with stable coronary artery disease. " 01/01/2008 - "This study was a sub-study of the EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease) trial (n = 12,218; mean follow-up 4.2 years). " Order ALL the reference details at left...
5.	Myocardial Infarction 07/01/2009 - "Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study." 04/01/2007 - "BACKGROUND: The aim of the study was to assess the effect on cardiac events of adding perindopril 8 mg once daily to standard preventive therapy in the subgroup of EUROPA patients with previous revascularization and without previous myocardial infarction (MI). " 03/27/2006 - "METHODS: Perindopril and Remodeling in Elderly With Acute Myocardial Infarction (PREAMI), a double-blind, randomized, parallel-group, multicenter, placebo-controlled study, determined whether similar benefits occur in elderly postinfarction patients with preserved left ventricular function. " 11/01/2005 - "The Perindopril and Remodelling in the Elderly with Acute Myocardial Infarction (PREAMI) is another trial recently terminated in elderly post-AMI patients with preserved left ventricular function. " 11/01/2005 - "The multicenter and international (109 centers from five European countries), double-blind, randomized, parallel PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infarction) trial evaluated the effects of the ACE-inhibitor perindopril in the elderly (aged > or =65 years) with AMI and preserved or mildly depressed left ventricular systolic function (ejection fraction > 40%). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Indapamide
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Enalapril
4.	Captopril (Capoten)
5.	Nifedipine (Adalat)
6.	Atenolol (Tenormin)
7.	Amlodipine (Norvasc)
8.	Losartan (Cozaar)
9.	Ramipril (Altace)
10.	Calcium Channels (Calcium Channel)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Aftercare (After-Treatment)
3.	Homologous Transplantation (Allograft)
4.	Microspheres (Microsphere)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Stroke

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2274 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>